ProSTAR: A Study Evaluating CPI-1205 in Patients With Metastatic Castration Resistant Prostate Cancer
Condition: Metastatic Castration Resistant Prostate Cancer (mCRPC) · Sponsor: Constellation Pharmaceuticals
About this study
This was an open-label Phase 1b/2 study involving oral administration of CPI-1205 in combination with either enzalutamide or abiraterone/prednisone in male patients with metastatic Castration-Resistant Prostate Cancer. The study was designed to determine the maximum tolerated dose (MTD) and the recommended Phase II dose (RP2D) based on the safety, tolerability, pharmacokinetic, and efficacy profiles of CPI-1205 in combination with either enzalutamide or abiraterone/prednisone. Following the determination of the MTD and RP2D, the study proceeded to Phase 2. Patients in Phase 2 received CPI-1205 at the RP2D in combination with either enzalutamide or abiraterone/prednisone versus either enzalutamide or abiraterone/prednisone as a control arm.
This description comes directly from the study's public registry record.
Talk to the study team
No contact information is available for this study as per the public registry record.
Always discuss trial participation with your own doctor first.
Locations (41)
| Alaska Urological Institute | Anchorage, Alaska, United States | — |
| Beverly Hills Cancer Center (BHCC) | Beverly Hills, California, United States | — |
| John Wayne Cancer Inst. | Duarte, California, United States | — |
| UCLA | Los Angeles, California, United States | — |
| Rocky Mountain Cancer Centers | Aurora, Colorado, United States | — |
| University of Colorado Hospital - Anschutz Cancer Pavilion | Aurora, Colorado, United States | — |
| University of Florida | Jacksonville, Florida, United States | — |
| Mount Sinai Comprehensive Cancer Center | Miami, Florida, United States | — |
| H. Lee Moffitt Cancer Center & Research Institute | Tampa, Florida, United States | — |
| Rush University Medical Center | Chicago, Illinois, United States | — |
| University of Illinois Hospital and Health Systems | Chicago, Illinois, United States | — |
| Indiana University- Simon Cancer Center | Indianapolis, Indiana, United States | — |
+ 29 more locations — full list on the registry record.
Follow this study
Save your interest here for when the public record changes — results posted, or the study's status changes. Email alerts for this study aren't switched on yet.
We keep this only about this public record, and never email you without alerts being switched on. Want it removed at any time? Email hello@eichor.com. Never medical advice. By subscribing you agree to our Terms of Use and Privacy Policy.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT03480646